Hydroxychloroquine study for rare clotting disorder halted early
NCT ID NCT02595346
First seen Feb 05, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study looked at whether adding hydroxychloroquine to standard treatment could improve blood vessel function in people with antiphospholipid syndrome, a condition that raises the risk of blood clots. About 25 adults were planned to take either hydroxychloroquine or a placebo alongside their usual care. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rouen University Hospital
Rouen, 76031, France
Conditions
Explore the condition pages connected to this study.